mutation pressure

mutation pressure的基本解释

-

突变压力

与mutation pressure相关的网络例句 [注：此内容来源于网络，仅供参考]

The production of various specifications of models of the general pressure gauge, pressure gauge in high pressure, pressure controller, pressure gauge controller, seismic pressure gauge, pressure gauge earthquake-resistant, resistance FarEasTone pressure gauge, dual scale pressure gauge calibration and three, stainless steel pressure gauge pressure recorder, oxygen pressure gauge, a wind pressure gauge diaphragm pressure gauges, diaphragm pressure gauges, diaphragm pressure gauge, pressure gauge needle, explosion-proof electric contact pressure gauges, explosion-proof induction type contact pressure gauge, ultra-high pressure manometer.

生产各种规格型号的普通压力表，中高压压力表，压力控制器，压力表式控制器，抗震压力表，耐震压力表，电阻远传压力表，双刻度及三刻度压力表，不锈钢压力表，压力记录仪，氧压力表，出风压力表膜盒压力表，膜片压力表，隔膜压力表，双针压力表，防爆电接点压力表、防爆感应式接点压力表，超高压压力表。

YMDD mutation: HBV YMDD mutation were developed in 12 lamivudine recipients, whereas the treated group had no incidence of HBV YMDD variation, there were significant difference between two groups (p=0.000). YMDD mutation resulted in increase of the mean HBVDNA levels (p=0.000), but no contribution to serum ALT diversification (p＞0.05). 2. Precore nt1896 mutation: Precore nt1896 mutation incidence had no difference between lamivudine recipients and objects who received combination therapy of Kidney-invigorating Granule and Marine Injection, and patients of HBeAg negative and HBeAg positive had a close incidence of precore mutation as well as. Precore nt1896 mutation had no influence on serum ALT level. The occurrence of precore nt1896 mutation contributed to serum HBVDNA load increased and worse response of HBVDNA extenuation. 3. HBV genotype: The baseline of serum HBVDNA gradually increase in turn of genotype B, genotype C and genotype B/C. Genotype B seemed to obtain higher rate of serum HBVDNA loss and HBeAg/anti-HBe seroconversion after combination therapy of Kidney-invigorating Granule and Marine Injection, differencing with lamivudine therapy.

疗效相关因素研究：1YMDD变异：对照组有12例检出YMDD变异，治疗组无1例检出，两组比较有显著性差异（P=0.000）；发生YMDD变异者血清HBVDNA和ALT水平均有所升高，HBVDNA平均水平高于非变异者（P=0.000）；血清ALT与非变异者无明显差异（P＞0.05）。2前C区nt1896变异：前C区nt1896变异发生率在治疗组和对照组以及HBeAg阴性和HBeAg阳性患者之间均无明显差异（P＞0.05）；1896c变异对血清ALT水平无明显影响；治疗组发生1896c变异者，其HBVDNA平均水平较之未变异者明显升高（P＜0.05），治疗后HBVDNA下降幅度明显低于未发生1896c变异者（P=0.000）。3HBV基因型：血清HBVDNA基础水平在B、C、B/C混合型间存在明显差异（P＜0.05），按B型、C型、B/C混合型依次升高；治疗组HBVDNA阴转率、HBeAg/抗-HBe血清转换率，B型似乎高于C型和B/C混合型，但无统计学意义（P＞0.05）；对照组HBVDNA阴转、HBeAg/抗-HBe改变在B、C、B/C混合型间无明显差异（P＞0.05）。

The result of uroscopy of the proband was strong positive. There was a novel deletion mutation of c.876-877 del TC in the coding region of exon 6 of IDS gene, which was a hemizygous mutation. However, the mutation of his mother and sister was a heterozygous mutation. Detection of the exon 6 of IDS gene showed that the mutation was not found among normal controls and other patients with MPS I, IV, and VI other than MPS II. Homology comparison of amino acid sequences from different species showed that the phenylalanine glutamine of the mutation site of c.876-877 del TC located in p.292-293 was highly conserved. The activity of IDS enzyme of the proband was only 2.3 nmol/4 h/mL, which was much lower than normal; but the activity of IDS enzyme of his father, mother and sister was 641.9 nmol/4 h/mL, 95.8 nmol/4h/mL and 103.2 nmol/4h/mL, respectively.

结果显示：先证者尿检呈强阳性；其IDS基因exon 6编码区内存在c.876-877 del TC新缺失突变，为半合子突变，而其母、其姐为杂合突变；正常对照和其他非II型MPS患者的IDS基因exon 6的检测结果均未发现该突变；不同物种氨基酸序列的同源性比对显示： c.876-877 del TC突变所在的位置即p.292-293的苯丙氨酸谷氨酰胺高度保守；酶活性测定的结果显示：先证者的IDS酶活性仅为2.3 nmol/4 h/mL，大大低于正常值，而其父的为641.9 nmol/4 h/mL，其母的血浆酶活性为95.8 nmol/ 4h/mL，其姐的为103.2 nmol/4 h/mL。

与mutation pressure相关的网络解释 [注：此内容来源于网络，仅供参考]

mutation pressure：突变压力[由突变而造成群体中基因频率的改变]

mutation 突变 | mutation pressure 突变压力[由突变而造成群体中基因频率的改变] | mutator 增变基因;增变株

mutation pressure：突变压力

突变期 mutation period | 突变压力 mutation pressure | 突变速率 mutation rate

mutation pressure：突变压力[由突变而造成群体中基因频檬的改变]

mutation 突变 | mutation pressure 突变压力[由突变而造成群体中基因频檬的改变] | mutator 增变基因;增变株